Myomo Reports Preliminary Fourth Quarter and Full Year 2019 Results CAMBRIDGE, MA.

Myomo Reports Preliminary Fourth Quarter and Full Year 2019 Results

CAMBRIDGE, MA., February 6, 2020 Myomo, Inc. (NYSE American: MYO) ( Myomo or the Company ), a wearable medical robotics

company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced preliminary financial and operational results for the fourth quarter and fiscal year ended December 31, 2019.

Key Preliminary Results for Q4 and 2019

This financial data as of and for the quarter and year ended December 31, 2019 is preliminary and may change, and is based on information available to

management as of the date hereof and is subject to completion by management of our financial statements as of and for the quarter and year ended December 31, 2019. There can be no assurance that our final results of operations for these periods

or cash position as of December 31, 2019 will not differ from these estimates, including as a result of review adjustments and any such changes could be material. Our independent registered public accountants have not audited, reviewed or

performed any procedures with respect to such preliminary financial data and accordingly do not express an

opinion or any other form of assurance with respect thereto. These results could change as a result of further review. Complete quarterly results and annual results will be included in our Annual

Report on Form 10-K for the year ended December 31, 2019.

Myomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis.

Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic

brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient s own EMG signals through non-invasive sensors on the arm, can

restore an individual s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is

headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Forward Looking Statements

This press release contains

forward-looking statements regarding the Company s future business expectations, including expected revenue for the quarter and year ended December 31, 2019, the growth in the Company s reimbursement pipeline, expected cash position

as of year-end 2019, the conversion of backlog into revenue and our expectations for revenue growth in 2020, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of

1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

include, among other things:

More information about these and other factors that potentially could affect our preliminary financial results is included in Myomo s filings with the

Securities and Exchange Commission, including those contained in the risk factors section of the Company s annual report on Form 10-K, quarterly reports on Form

10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking

statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or

outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from

them will not be material and adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such

statements or to reflect the occurrence of anticipated or unanticipated events.

Matter Communications